PDF(Pubmed)
Abstract：
UNASSIGNED: Repetitive transcranial magnetic stimulation (rTMS) is an effective noninvasive neuromodulation technique for Parkinson\'s disease (PD). However, the efficacy of rTMS varies widely between individuals. This study aimed to investigate the factors related to the response to rTMS in PD patients.
UNASSIGNED: We retrospectively analyzed the response of 70 idiopathic PD patients who underwent rTMS for 14 consecutive days targeting the supplementary motor area (SMA) in either an open-label trail (n = 31) or a randomized, double-blind, placebo-controlled trial (RCT) (n = 39). The motor symptoms of PD patients were assessed by the United Parkinson\'s Disease Rating Scale Part III (UPDRSIII). Based on previous studies, the UPDRSIII were divided into six symptom clusters: axial dysfunction, resting tremor, rigidity, bradykinesia affecting right and left extremities, and postural tremor. Subsequently, the efficacy of rTMS to different motor symptom clusters and clinical predictors were analyzed in these two trails.
UNASSIGNED: After 14 days of treatment, only the total UPDRSIII scores and rigidity scores improved in both the open-label trial and the RCT. The results of multiple linear regression analysis indicated that baseline rigidity scores (β = 0.37, p = 0.047) and RMT (β = 0.30, P = 0.02) positively predicted the improvement of UPDRSIII. The baseline rigidity score (β = 0.55, P < 0.0001) was identified as an independent factor to predict the improvement of rigidity.
UNASSIGNED: This study demonstrated significant improvements in total UPDRSIII scores and rigidity after 14-day treatment, with baseline rigidity scores and RMT identified as predictors of treatment response, underscoring the need for individualized therapy.
UNASSIGNED: We retrospectively analyzed the response of 70 idiopathic PD patients who underwent rTMS for 14 consecutive days targeting the supplementary motor area (SMA) in either an open-label trail (n = 31) or a randomized, double-blind, placebo-controlled trial (RCT) (n = 39). The motor symptoms of PD patients were assessed by the United Parkinson\'s Disease Rating Scale Part III (UPDRSIII). Based on previous studies, the UPDRSIII were divided into six symptom clusters: axial dysfunction, resting tremor, rigidity, bradykinesia affecting right and left extremities, and postural tremor. Subsequently, the efficacy of rTMS to different motor symptom clusters and clinical predictors were analyzed in these two trails.
UNASSIGNED: After 14 days of treatment, only the total UPDRSIII scores and rigidity scores improved in both the open-label trial and the RCT. The results of multiple linear regression analysis indicated that baseline rigidity scores (β = 0.37, p = 0.047) and RMT (β = 0.30, P = 0.02) positively predicted the improvement of UPDRSIII. The baseline rigidity score (β = 0.55, P < 0.0001) was identified as an independent factor to predict the improvement of rigidity.
UNASSIGNED: This study demonstrated significant improvements in total UPDRSIII scores and rigidity after 14-day treatment, with baseline rigidity scores and RMT identified as predictors of treatment response, underscoring the need for individualized therapy.
摘要：
■重复经颅磁刺激（rTMS）是帕金森病（PD）的一种有效的非侵入性神经调节技术。然而,rTMS的疗效在个体之间差异很大。本研究旨在探讨PD患者对rTMS反应的相关因素。
■我们回顾性分析了70例特发性PD患者的反应，这些患者连续14天接受rTMS，以开放标记（n=31）或随机，双盲,安慰剂对照试验（RCT）（n=39）。采用帕金森病联合评定量表第三部分(UPDRSIII)对PD患者的运动症状进行评估。根据以前的研究，UPDRSIII分为六个症状群：轴向功能障碍，静止性震颤,刚性,影响左右四肢的运动迟缓，和姿势震颤。随后，分析了rTMS对不同运动症状群和临床预测因子的疗效。
■治疗14天后，在开放标签试验和RCT中,只有UPDRSIII总评分和刚性评分得到改善.多元线性回归分析结果表明，基线刚性评分（β=0.37，p=0.047）和RMT（β=0.30，P=0.02）正预测UPDRSIII的改善。基线刚度评分（β=0.55，P<0.0001）被确定为预测刚度改善的独立因素。
■这项研究表明，经过14天的治疗，UPDRSIII总评分和僵硬度得到了显着改善，基线刚性评分和RMT被确定为治疗反应的预测因子，强调个性化治疗的必要性。
■我们回顾性分析了70例特发性PD患者的反应，这些患者连续14天接受rTMS，以开放标记（n=31）或随机，双盲,安慰剂对照试验（RCT）（n=39）。采用帕金森病联合评定量表第三部分(UPDRSIII)对PD患者的运动症状进行评估。根据以前的研究，UPDRSIII分为六个症状群：轴向功能障碍，静止性震颤,刚性,影响左右四肢的运动迟缓，和姿势震颤。随后，分析了rTMS对不同运动症状群和临床预测因子的疗效。
■治疗14天后，在开放标签试验和RCT中,只有UPDRSIII总评分和刚性评分得到改善.多元线性回归分析结果表明，基线刚性评分（β=0.37，p=0.047）和RMT（β=0.30，P=0.02）正预测UPDRSIII的改善。基线刚度评分（β=0.55，P<0.0001）被确定为预测刚度改善的独立因素。
■这项研究表明，经过14天的治疗，UPDRSIII总评分和僵硬度得到了显着改善，基线刚性评分和RMT被确定为治疗反应的预测因子，强调个性化治疗的必要性。
